Brief: Mira Pharmaceuticals Inc - Enrolls First Subjects In Phase 1 Trial For Ketamir-2 - SEC Filing
01/04/2025 12:33
April 1 (Reuters) - Mira Pharmaceuticals Inc MIRA.O: MIRA PHARMACEUTICALS INC - ENROLLS FIRST SUBJECTS IN PHASE 1 TRIAL FOR KETAMIR-2 - SEC FILING MIRA PHARMACEUTICALS INC - PHASE 1 STUDY EXPECTED TO COMPLETE BY Q4 2025 - SEC FILING MIRA PHARMACEUTICALS INC - FIRST HUMAN EFFICACY DATA EXPECTED IN H1 2026 Source text: [ID:n0001641172-25-001987] Further company coverage: MIRA.O (((( Reuters.briefs@thomsonreuters.com ;));))
Recent news on Mira Pharmaceuticals
See all newsBrief: Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: MIRA Pharmaceuticals Secures Worldwide Exclusive Rights To MIRA-55 And SKNY-1 - SEC Filing
Brief: Mira Pharmaceuticals Enters Into Amendment No 1 To Exclusive License Agreement With Miralogx
Brief: Mira Pharmaceuticals Inc - Completes Phase 1 Dosing Of Ketamir-2 - SEC Filing
Brief: Mira Pharmaceuticals Inc - Initiates Phase 1 Study Of Ketamir-2 - SEC Filing